Regeneron Pharmaceuticals (REGN) Net Equity Issued and Repurchased (2009 - 2026)

Regeneron Pharmaceuticals' Net Equity Issued and Repurchased history runs 18 years deep, the most recent figure standing at $49.2 million for Q2 2026.

• In Q2 2026, Net Equity Issued and Repurchased rose 56.19% year-over-year to $49.2 million; the TTM figure through Jun 2026 stood at $756.1 million (up 72.74% YoY), while the FY2025 annual figure was $635.9 million, down 56.6% from the prior year.
• Net Equity Issued and Repurchased for Q2 2026 stood at $49.2 million, down from $163.1 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $682.1 million in Q1 2024, with the low at $31.5 million in Q2 2025.
• The 5-year median for Net Equity Issued and Repurchased is $284.8 million (2023), against an average of $276.6 million.
• Peak annual rise in Net Equity Issued and Repurchased reached 453.91% in 2025, while the deepest fall reached 92.8% in 2025.
• Regeneron Pharmaceuticals' Net Equity Issued and Repurchased stood at $372.6 million in 2022, then declined by 19.22% to $301.0 million in 2023, then sank by 69.8% to $90.9 million in 2024, then jumped by 453.91% to $503.5 million in 2025, then sank by 90.23% to $49.2 million in 2026.
• Business Quant data shows REGN's Net Equity Issued and Repurchased at $49.2 million in Q2 2026, $163.1 million in Q1 2026, and $503.5 million in Q4 2025.